Rituximab

Rituximab is a type of monoclonal antibody used to treat a variety of medical conditions. It binds to a molecule called CD20 which is found on the surface of certain types of white blood cells, mainly B-cells. By binding to CD20, rituximab can reduce the number of B-cells in the body and reduce inflammation. It is primarily used to treat Non-Hodgkin’s Lymphoma and Rheumatoid Arthritis, but can also be used to treat a variety of other autoimmune and malignant disorders. Rituximab is considered a very effective treatment option and has improved outcomes for many patients.

← International Journal of Multiple Sclerosis and Related Disorders

Related Topics

Ozanimod Melanoma Cells Microbiome Cerebrovascular Disease Hardening of the Arteries. Nootropics Cladribine

Related Articles

1 journal(s) found

International Journal of Multiple Sclerosis and Related Disorders

ISSN: Coming Soon
Type: Open Access Journal
Editor: Derrick Robertson, University of South Florida, Morsani College of Medicine, Department of Neurology, MS Division.
The Journal of Sclerosis is an online, open-access, peer-reviewed journal which concentrates mainly on the field of sclerosis. JSC accepts all types of articles, including research, reviews, short communications, editorials, and case reports in all fields of sclerosis; also, it encourages researchers and academics to upgrade according to the
Aim & Scope Submit Manuscript Call for Papers